Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `jetpack` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /var/www/wp-includes/functions.php on line 5835
Uncategorized – Force Pharma Capital
Skip to content
Force Pharma Capital
Force Pharma Capital
Life Science Consulting, Business Development and Recruiting/Staffing
  • Home
  • About Us
  • Services
  • Pharmaceutical Blog
    • RLD
    • Excipients
    • Equipment
    • Health Technology
    • Regulatory Fees
  • Contact Us
  • FAQ
  • Portfolio

Category: Uncategorized

First Generic Drug Approvals | FDA

January 11, 2020 Blogger

Each year, FDA’s Center for Drug Evaluation and Research (CDER) approves a wide range of new drug products. FDA provides…

Continue Reading →

Posted in: Uncategorized Filed under: approvals, FDA, gdufa

FDA Updates List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic

December 13, 2019 Blogger

FDA Updates List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic — Read on s2027422842.t.en25.com/e/es

Continue Reading →

Posted in: Uncategorized Filed under: approvals, FDA, gdufa

FDA Announces Availability of Draft Guidance – Drug Master Files

October 18, 2019 Blogger

FDA Announces Availability of Draft Guidance – Drug Master Files — Read on s2027422842.t.en25.com/e/es

Continue Reading →

Posted in: Uncategorized Filed under: FDA

FDA approves new treatment for patients with migraine | FDA

October 11, 2019 Blogger

The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine…

Continue Reading →

Posted in: Uncategorized Filed under: approvals, pdufa

First Generic Drug Approvals | FDA

October 1, 2019 Blogger

Each year, FDA’s Center for Drug Evaluation and Research (CDER) approves a wide range of new drug products. FDA provides…

Continue Reading →

Posted in: Uncategorized Filed under: FDA, gdufa

Statement alerting patients and health care professionals of NDMA found in samples of ranitidine | FDA

September 14, 2019 Blogger

The U.S. Food and Drug Administration has learned that some ranitidine medicines, including some products commonly known as the brand-name…

Continue Reading →

Posted in: Health Technology, Uncategorized Filed under: FDA

New Study Points to Targetable Protective Factor in Alzheimer’s Disease – NIH Director’s Blog

September 11, 2019 Blogger

New Study Points to Targetable Protective Factor in Alzheimer’s Disease – NIH Director’s Blog — Read on directorsblog.nih.gov/2019/09/10/new-study-points-to-targetable-protective-factor-in-alzheimers-disease/

Continue Reading →

Posted in: Uncategorized

Certain Prostate Cancer Therapies Increase Risks for Patients with Pre-existing Heart Disease

August 28, 2019 Blogger

The effect of oral androgen signaling inhibitor therapies on patients with pre-existing cardiovascular disease may increase the risk of death.…

Continue Reading →

Posted in: Uncategorized Filed under: fixed dose combination

Statement on the agency’s ongoing efforts to resolve safety issue with ARB medications | FDA

Blogger

The FDA is issuing an update regarding the ongoing efforts to resolve safety issues with ARB medications. — Read on…

Continue Reading →

Posted in: Uncategorized

Statement on the agency’s ongoing efforts to resolve safety issue with ARB medications | FDA

Blogger

The FDA is issuing an update regarding the ongoing efforts to resolve safety issues with ARB medications. — Read on…

Continue Reading →

Posted in: Uncategorized Filed under: gdufa

Post navigation

Page 1 of 3
1 2 3 Next →

Recent Posts

  • Most Recent Changes to the IID Database | FDA
  • The History, Benefits of Pharmaceutical REMS Programs
  • FDA approves first drug for treatment of peanut allergy for children

Recent Comments

  • flower bouquet delivery online on FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma
  • cheap flowers online same day delivery on Trending News Today: Investigational Long-Acting HIV Injection Shows Efficacy in Study
  • flower arrangements for baby shower girl on FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma

Archives

  • August 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • November 2018

Follow Us

Contact Us

  • Email
    forcepharma@icloud.com
  • Phone
    732-702-1824
  • Address
    265 Route 34 Lower Level, Colts Neck, New Jersey, 07722
Copyright © 2018 Force Pharma Capital